Technology: Overview

As a discovery company, we are focused on finding and developing treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep infection, cancer and certain other autoimmune and infectious diseases. Two approaches developed by Dr. M. Karen Newell-Rogers form the basis of our research: Targeted Peptides Therapies (TPT) and Metabolic Disruption Technology (MDT). All of our compounds are in the late preclinical stage and we are now preparing to submit pre-IND documents to the FDA for clinical trials in the US. An investigator’s IND for our glioblastoma therapy using an MDT approach is planned for January 2011.

TPTs are custom-designed protein fragments that work to modify certain immune system reactions that we believe cause or worsen some inflammatory diseases. The TPT compounds we are studying represent in some sense the second generation of our earlier TNP therapy. MDT encompasses a way to change how some types of cells use fat, amino acids and sugars or carbohydrates for energy. By manipulating metabolic processes, we can cause some harmful cells – including drug-resistant cancer cells – to die. The same MDT approach has also recently been discovered to have potential in encouraging the production and storage of biofuels from algae and other plants.